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Edited by Ned ManteiAbstract Yap8p, a member of the Saccharomyces cerevisiae
Yap family, is activated in response to arsenic. Both the
mechanisms by which this activation takes place and its
regulation have not yet been identiﬁed. In this report, we show
that Yap8p is not activated at the transcriptional level but,
rather, its nuclear transport is actively regulated and dependent
on the exportin chromosome region maintenance protein. In
addition, it is shown that Cys132, Cys137and Cys274 are essential
for Yap8p localization and transactivation function both of
which are required for its biological activity.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Saccharomyces cerevisiae arsenic compounds resistance
(ACR) cluster was isolated as loci that increase tolerance to
arsenite [1]. The three contiguous genes identiﬁed as ACR1
(YAP8), ACR2 and ACR3 encode a positive regulator, an
arsenate-reductase and a plasma membrane arsenite eﬄux
protein, respectively [2–5]. ACR1, also designated YAP8, be-
longs to the yeast AP-1 like factor (YAP) family of tran-
scription factors [6]. Members of the YAP family (Yap1p to
Yap8p) share a conserved bZIP DNA-binding domain, each
regulating a speciﬁc set of genes involved in multi-drug resis-
tance [7]. Yap8p could mediate arsenic stress responses by
regulating the expression of ACR2 and ACR3. Yeast cadmium
factor 1 (Ycf1p) is also involved in the arsenite detoxiﬁcation
and known for conferring resistance to a variety of drugs
through sequestering the glutathione S-conjugates into the
vacuole [8]. Yap1p [9], the prototypical YAP gene family,
which regulates the yeast oxidative stress response regulon,
also regulates the expression of YCF1. Yap1p primary control
lies in a redox-regulated Crm1-dependent nuclear export [10–
12]. Redox signals disrupt the Yap1p–chromosome region
maintenance protein (Crm1p) interaction through a redox-* Corresponding author. Fax: +351-214-433-644.
E-mail address: claudina@itqb.unl.pt (C. Rodrigues-Pousada).
Abbreviations: ACR, arsenic compounds resistance; YAP, yeast AP-1
like factor; YCF, yeast cadmium factor; Crm1p, chromosome region
maintenance protein
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doi:10.1016/j.febslet.2004.04.019dependent alteration of the Yap1p C-terminal nuclear export
signal (NES), thereby promoting Yap1 nuclear accumulation.
Data presented here show that arsenic compounds activate
Yap8p at the level of both its nucleo-cytoplasmic shuttling and
its transactivation potential. Regulation of Yap8p nucleo-
cytoplasmic shuttling involves arsenic-sensitive Crm1p-depen-
dent nuclear export and the Yap8 cysteine residues located in
positions 132, 137 and 274.2. Materials and methods
2.1. Growth conditions
Yeast strains were grown in complete YPD (1% yeast extract, 2%
bactopeptone, 2% glucose) or selective media (SC or SD: 0.67% am-
monium sulfate-yeast nitrogen base without amino acids [Difco], 2%
glucose), supplemented with the appropriate selective amino acids.
Early exponential phase cells (A600 ¼ 0:4–0:5) were induced by the
addition of 2 mM Na2HAsO or NaAsO2 and samples collected at the
indicated time point. Samples for RNA and protein extraction were
washed and stored at )80 C. Phenotypic growth assays were carried
out by spotting 5 ll of an early exponential phase diluted culture
(approximately 2 103 cells) in medium containing increasing con-
centrations of Na2HAsO or NaAsO2. Growth was recorded after 2
days at 30 C. The bacterial Escherichia coli strain XL1-Blue recA1
endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F0proAB lacIqZDM15
Tn10 (Tetr)] (Stratagene) was used as the host for routine cloning
purposes. Standard methods were used for genetic analysis, cloning
and transformation [13] (see Table 1).
2.2. Plasmids and constructs
To express the YAP8 gene the corresponding chromosomal region
was ampliﬁed by PCR. The product was ﬁrst cloned using the Zero
Blunt TOPO PCR Cloning Kit (Invitrogen) and the KpnI fragment,
encoding the entire YAP8 ORF plus 923 bp upstream and 643 bp
downstream, sub-cloned into the CEN vector YEplac33 [18] to gen-
erate construct YCpYAP8. To create the YAP8-TAPtag chimera XhoI
and NcoI restriction sites were introduced by PCR, the product was
ﬁrst cloned into the vector pBS1479 and subsequently sub-cloned into
the pRS416 [19]. The fusion GFP-YAP8 (pRS cp-GFP-HA-YAP8) was
obtained by replacing the PvuII/SalI YAP4 gene in the plasmid pRS
cp-GFP-HA-YAP4 [20]. The lexA-YAP8 constructions were generated
by cloning the respective SmaI/KpnI PCR products into the YCp91
expression vector [6]. Site-directed mutagenesis of YAP8 cysteines was
performed by PCR ampliﬁcation of entire plasmids using comple-
mentary primers containing the desired mutation. All constructs were
sequenced using the ABI Prism DyeDeoxy Terminator Cycle Se-
quencing Kit (Applied Biosystems) and ABI Prism 373A Automatic
Sequencer (Perkin Elmer). The fusion proteins were functional since
they complement yap8 mutant.
2.3. Northern-blot analysis
RNA procedures were performed according to [15]. RNA was iso-
lated from early log-phase cultures (A600 ¼ 0:4–0:5) that were eitherblished by Elsevier B.V. All rights reserved.
Fig. 1. yap8 and yap1 deleted strains show distinct sensitivity to ar-
senic. Tolerance of the yap8mutant is rescued by expressing YAP8 in a
CEN-based plasmid. Approximately 2 103 early exponential phase
cells were spotted onto YPD (A) or SC (B) medium supplement with
increased concentrations of arsenate (AsV) and arsenite (AsIII).
Fig. 2. Induction of genes involved in arsenic stress response. Early exponenti
the indicated time-points. RNAs and proteins were extracted as described. No
and YAP1. U3 mRNA was used as internal loading control and the HSP26
YAP8-TAPtag were assayed for immunoblot.
Table 1
S. cerevisiae strains used in this study
Strain Genotype Source
FY1679 MATa his3-200 ura3-52 GAL2 Winston et al. [14]
FYD1 Mata his3-200 ura3-52 GAL2 yap1::KAN Nevitt et al. [15]
BY 4743 MATa/a his3D1/his3D1 leuD0/leuD0 lys2D0/LYS2 met15D0/MET15 ura3D0/ura3D0
YPR199c::kanMX4/YPR199c::kanMX4 (isogenic to FY strains)
EUROSCARF
BYD8 MATa his3D1 leuD0 met15 D0lys2D0 ura3D0 YPR199c::kanMX4 This study
BYD1D8 MATa yap1::HIS3 leuD0 met15D0 lys2D0 ura3D0 YPR199c::kanMX4 This study
FT4 MATa ura3-5 trp1-D63 his3-D200 leu2::PET56 Tzamarias and Struhl [16]
mcy8 Mata his3 can1-100 ade2 leu2 trp1 yap1::URA3 ura3::(3XSV40AP1-lacZ)
crm1::HIS3-pmet3-CRM1
Kuge et al. [11]
L40a MATa ade2 trp1-901 leu2-3 112 his3-200 LYS::lexA-His3 URA3::lexA op-lacZ Marcus et al. [17]
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40 lg of RNA were separated in formaldehyde gels, and transferred
onto nylon membranes (Hybond XL, Amersham Pharmacia Biotech).
The following intragenic PCR fragments were used as probes: 0.84 kb
YAP8, 1.80 kb YAP1, 0.38 kb ACR2, 0.38 kb ACR3, 0.80 kb YCF1,
0.60 kb HSP26, 0.20 kb U3. mRNA levels were quantiﬁed (Image-
Quant, Molecular Dynamics) and normalized against those of U3 in-
ternal loading control, a small nuclear RNA (SNR17A).2.4. Protein extraction and Immunoblot analysis
Samples collected at the indicated time points were harvested by
centrifugation at 4 C. Protein extracts were prepared by the TCA acid
lysis method and immunoblotted according to [15]. To measure in-
tracellular levels of TAPtag-Yap8p and LexA-Yap fusion proteins,
immunoblotting was performed with 100 and 50 lg of proteins, re-
spectively. The LexA-hybrid proteins were detected using a monoclo-
nal LexA antibody (Clontech) and anti-mouse IgG conjugated to
alkaline phosphatase (Bio-Rad). Detection was performed using the
AP Conjugate Substrate Kit (Bio-Rad).al phase cells were up-shifted to 2 mM of AsV or AsIII and harvested at
rthern-blot analysis of (A) ACR2 and ACR3, (B) YCF1 and (C) YAP8
as an inducing control of arsenic stress. (D) Cells expressing the fusion
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Cells transformed with pRS cp-GFP-HA-YAP8 were grown to early
log phase and induced with either 2 mM Na2HAsO or NaAsO2, at
the indicated time points. 4,6-Diamino-2-phenylindole (DAPI) was
added as a DNA marker at a ﬁnal concentration of 20 lg/ml, 5 min
before microscopy. After washing with phosphate-buﬀered saline
(PBS), cells were resuspended in DABCO solution (75% glycerol,
0.25 PBS and 200 mM diazabicyclooctane, Sigma–Aldrich). Our
own experience and the one of Delaunay and co-workers [21] have
shown that DABCO does not aﬀect GFP-Yap8 localization. Fluo-
rescence of live yeast cells was visualized by a Leica DMBR ﬂuo-
rescence microscope.
2.6. b-Galactosidase activities
Cells expressing LexA fusions were replica-plated onto SD medium
containing 2 mM Na2HAsO or NaAsO2 and after two days covered
with 10 ml of 0.5 M sodium phosphate buﬀer (pH 7.0); 0.2% (w/v)
SDS; 2% (v/v) dimethyl formamide containing 100 mg X-gal/ml and
0.5% (w/v) agarose at 70 C. Plates were analyzed after 30 min – 24 h
incubation at 30 C. For quantitative b-galactosidase measurements,
cells were harvested in early log phase, permeabilized with chloroform
and assayed for enzyme activity.Fig. 3. Yap8p and Yap1p are relocated to the nucleus upon arsenic
treatment. (A) Cells grown to early exponential phase were induced 10
min with 2 mM of arsenate and analysed under a ﬂuorescence mi-
croscope. (B) Cells expressing the CRM1 driven by the MET3 pro-
moter were grown to early exponential phase in the presence or
absence of methionine. PHY, physiological conditions (C) Dyap1 or
Dorp1 strains expressing GFP-Yap1, or its mutant derivatives were
induced 10 min with 2 mM of AsIII or AsV and analyzed by ﬂuo-
rescence microscopy.3. Results and discussion
3.1. YAP8 is required for resistance to arsenic compounds and
for a regulated expression of the ACR2, ACR3 and YCF1
genes
A strain lacking the YAP8 gene (Dyap8) is highly sensitive to
arsenate and arsenite at very low concentrations (100 lM)
(Fig. 1A). In comparison, the isogenic wild-type strain toler-
ates up to 2 mM of both drugs. The Dyap8 arsenic phenotype
is rescued by reintroducing YAP8 on a centromeric plasmid
(Fig. 1B). A strain lacking YAP1 is also hypersensitive to both
drugs (Fig. 1A). A strain lacking both yap1 and YAP8 is even
more sensitive to arsenic compounds than either of the single
mutant strains (Fig. 1A), indicating that both YAP1 and
YAP8 are independently required for the cell tolerance to ar-
senic compounds.
The expression of ACR2, ACR3 and YCF1 is induced by
arsenic stress (Figs. 2A and B), with arsenate having a much
potent eﬀect than arsenite. This induction is decreased or
even abolished in Dyap8 (Fig. 2A). Induction of these genes
by arsenic compounds is also diminished in Dyap1, consis-
tent with the notion that both ACR3 [22] and YCF1 [9] are
known Yap1-target genes. The requirement of both YAP1
and YAP8 for arsenic stress tolerance can thus be ratio-
nalized by their function of regulating the arsenic stress-in-
duction of genes important for arsenic compounds
detoxiﬁcation.
3.2. Yap8p is redistributed to the nucleus upon arsenic treatment
We explored the mechanism of Yap8 activation by arsenic
compounds. Transcriptional activation is not a major deter-
minant in this activation since YAP8mRNA and protein levels
are constitutive and not induced upon arsenic treatment (Figs.
2C and D). In contrast, YAP1 mRNA levels are slightly in-
duced by arsenic compounds (Fig. 2C) indicating that Yap1
might participate in the arsenic stress response.
Since Yap1p is regulated at the level of a Crm1-dependent
nuclear export [10,12,23] we investigated whether a similar
mechanism could apply to Yap8p by monitoring the cell dis-
tribution of a GFP-Yap8 fusion protein. Yap8 appeared pre-
dominantly localized in the cytoplasm under non-stress
conditions and redistributed into the nucleus within 10 minafter arsenic treatment (Fig. 3A). Arsenate had the eﬀect of
keeping Yap8 longer in the nucleus than arsenite (data not
shown), probably due to the delayed detoxiﬁcation of this
compound that needs a reduction step to arsenite.
We next investigated the involvement of Crm1p in Yap8 cell
redistribution using a strain carrying CRM1 under control of a
methionine-repressible promoter [11]. In non-stressed cells,
GFP-Yap8 appeared in the nucleus in the presence of methi-
onine but was cytoplasmic when methionine was absent
(Fig. 3B). These data establish that Crm1 mediates Yap8 nu-
clear export and suggest that this export is regulated by arsenic
stress.3.3. C132, C137 and C274 are essential for Yap8p nuclear
translocation
In analogy to Yap1, which can respond to cysteine-reactive
chemicals through its modiﬁcation at speciﬁc cysteine residues
[12,23,24], we investigated the requirement of Yap8 cysteine
residues in Yap8 activation by arsenic compounds.
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higher homology, one being in the C-terminus of these pro-
teins (Fig. 4A). The corresponding Yap1 C-terminal domain,
also called c-CRD for C-terminal cysteine-rich domain carries
the Crm1-cognate NES comprising a leucine-rich hydropho-
bic amino acid stretch embedded in a three-repeat cysteine
motif (Cys598, Cys620, Cys629) [10]. Yap8 also contains a pu-
tative NES in the corresponding domain, previously identiﬁed
by a short leucine-rich hydrophobic amino-acid sequence
ﬂanked by positively charged residues (amino acids 240–282)
[22]. However, this Yap8 C-terminal domain only contains
one cysteine residue (C274) that appears conserved with Yap1
Cys629. The second domain of high homology corresponds to
the Yap1 n-CRD that also carries a three-repeat cysteine
motif (Cys303, Cys310, Cys315). In the corresponding region
Yap8p carries two cysteines (C132 and C137) that are con-Fig. 4. (A) Comparison of Yap8p and Yap1p. (B) Yap8p cysteines (underline
ﬂuorescence microscopy after 10 min induction with 2 mM AsV. (C) Phenoty
its mutated versions. (D) Dyap8 cells expressing YAP8-TAPtag fusion and its
immunoblotting.served with Yap1p Cys310 and Cys315, respectively. Taking
into account the structural similarities between Yap8p and
Yap1p we anticipated that Yap8p conserved cysteines might
play a role in the regulation of Yap8 nuclear export. Yap8
C132, C137 and C274 were individually and simultaneously
substituted with alanine residues. These mutations all im-
paired the nuclear relocalization of Yap8p in response to
arsenate (2 mM) (Fig. 4B) and the ability of Yap8 to restore
resistance to arsenic compounds to the Dyap8 strain
(Fig. 4C). In contrast, the GFP-Yap8p clearly restores the
As-phenotype of the yap8 mutant. These cysteine substitu-
tions do not aﬀect the stability of Yap8 as shown by Western
blot (Fig. 4D). We suggest that arsenic compounds inhibit
Crm1-dependent Yap8 nuclear export by binding to these
cysteine residues thereby inhibiting Yap8–Crm1 interaction
through a change of conformation.d) were substituted by alanine and nuclear redistribution monitored by
pic analysis of the yap8 mutant expressing the GFP-YAP8 chimera and
cysteine mutants were induced 10 min with 2 mM AsV and assayed by
Fig. 5. Yap8p and Yap1p transactivation potential. (A) Cells co-
expressing the Lex-Yap fusions and a reporter cassette bearing the
lacZ gene driven by a promoter containing the LexA binding se-
quence were grown in the presence and absence of arsenic. Values
of b-galactosidase activities (average of six independent transfor-
mants) are normalized to the A600 of cells and accurate to 15%.
PHY, physiological conditions; N.D. not detected. (B) Arsenic
sensitivity of the yap8 mutant expressing, lexA-YAP8 and its mu-
tated versions.
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treatment
The function of transactivation can be another level of
control for a transcription factor. We thus investigated whe-
ther arsenic compounds could modulate the Yap8 transacti-
vation function using a one-hybrid strategy [25]. A LexA-Yap8
fusion protein, containing an artiﬁcial NLS, was able to acti-
vate transcription of the lacZ reporter gene from a LexA op-
erator and this activation was increased upon arsenate
treatment. Arsenite had only a slight or no eﬀect on lacZ gene
activation by LexA-Yap8 (Fig. 5A). Interestingly, the trans-
activation potential of LexA-Yap8p under arsenate is of the
same order of magnitude as LexA-Yap2p under cadmium [6].
The ability of the LexA-Yap8 fusion to rescue the Dyap8 ar-
senic phenotype demonstrates that this fusion retains the Yap8
intrinsic molecular function in arsenic resistance (Fig. 5B). We
next sought mapping the Yap8 transactivation domain by
testing various Yap8 truncations in the one-hybrid assay (see
diagram of Fig. 5A). None of the tested constructs could ac-
tivate lacZ transcription thus indicating that only full-length
Yap8 retains the function of transactivation. We also tested
the possible requirement of Cys132, Cys137 and Cys274 in this
function. Interestingly, alanine substitution of each of these
cysteines abolished lacZ gene expression by the Lex-Yap8 fu-
sion indicating that these residues are also important for the
Yap8 function of transactivation (Fig. 5A). However, as can
be seen in Fig. 5B, LexA-Yap8 fusion mutated in the Cys137partially restores the As-phenotype of the yap8 mutant. It is
therefore plausible that Cys137 does not play a relevant phys-
iological role in the Ya8p activity as play the Cys132 and
Cys274.3.5. Yap1 activation by arsenic compounds is distinct from
H2O2 activation and similar to activation by thiol-reactive
chemicals
A GFP-Yap1 fusion potently accumulated in the nucleus
upon treatment with arsenic compounds (Fig. 3C), indicat-
ing that Yap1 activation by these chemicals is exerted at the
level nuclear export as for its activation by H2O2 and by
thiol-reactive chemicals [24]. Yap1 cannot be activated by
H2O2 in cells lacking Orp1/Gpx3, a GPx-like peroxidase
that acts as the sensor of the pathway [12]. In cells lacking
Orp1, GFP-Yap1 still potently accumulated in the nucleus
upon treatment with arsenic compounds indicating a
mechanism distinct from H2O2. Further, an NLS-GFP-c-
CRD fusion protein [24] also accumulated in the nucleus
upon arsenite and arsenate treatment while GFP-Yap1
carrying substitution of all three c-CRD cysteines was un-
responsive to these chemicals. Thus, Yap1 activation by
arsenic compounds involves c-CRD cysteines and therefore
uses a mechanism similar to that activated by thiol-reactive
chemicals.
In contrast to Yap8p, arsenic compounds did not signiﬁ-
cantly modulate Yap1 transactivation function.4. Conclusion
In conclusion, Yap8p is an important regulator of genes
involved in arsenic compounds detoxiﬁcation. Activation of
Yap8p involves an arsenite- and arsenate-sensitive Crm1-
dependent nuclear export. Yap8 Cys132, Cys137, and Cys274 are
crucial in this regulated export. Arsenic compounds probably
regulate Yap8 nuclear export by modifying its cysteine resi-
dues and hence the NES, in analogy with the activation of
Yap1 by these same compounds and by other thiol-reactive
chemicals. Thus, Yap8 and Yap1 share a conserved mecha-
nism of activation by arsenic compounds. A recent paper
also identiﬁed Yap8 as a regulator of the S. cerevisiae arse-
nite and arsenate response. This study also suggested a reg-
ulation of Yap8 at the level of its transactivation function,
consistent with our results (Fig. 5). Surprisingly these authors
found Yap8 constitutively nuclear [26] which contrast with
the data shown here. The reason for this discrepancy is not
clear, but could be related to unknown genetic diﬀerences in
the S. cerevisiae strains used. These diﬀerences cannot be
attributed to Ybp1, a protein required for Yap1 activation by
H2O2 and known for being mutated in some S. cerevisiae
strains [27], since activation of both Yap8 and Yap1 by ar-
senic compounds is independent of this factor (data not
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